If you need any assistance voting your shares,
please contact our proxy solicitor at:
D.F. King & Co, Inc.
48 Wall Street, 22nd Floor
New York, NY 10005
Call Toll-Free: (800) 347-4750
Banks and Brokers Call: (212) 269-5550
BIOLASE is a medical device company that develops, manufactures,
markets, and sells laser systems in dentistry and medicine.
BIOLASE’s products advance the practice of dentistry and medicine
for patients and healthcare professionals. BIOLASE’s proprietary
laser products incorporate approximately 271 patented and 40
patent-pending technologies designed to provide biologically and
clinically superior performance with less pain and faster recovery
times. BIOLASE’s innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE’s principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 41,200 laser systems to date in
over 80 countries around the world. Laser products under
development address BIOLASE’s core dental market and other adjacent
medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase
laser dentistry, find BIOLASE online at www.biolase.com, Facebook
at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc,
Instagram at www.instagram.com/waterlase_laserdentistry, and
LinkedIn at www.linkedin.com/company/biolase.
Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking
This communication contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements,
regarding the anticipated effects of stockholder approval of
matters to be voted on at BIOLASE’s 2021 annual meeting of
stockholders (the “Annual Meeting”). Forward-looking statements can
be identified through the use of words such as may,” “might,”
“will,” “intend,” “should,” “could,” “can,” “would,” “continue,”
“expect,” “believe,” “anticipate,” “estimate,” “predict,”
“outlook,” “potential,” “plan,” “seek,” and similar expressions and
variations or the negatives of these terms or other comparable
terminology. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE’s current
expectations and speak only as of the date of this communication.
Actual results may differ materially from BIOLASE’s current
expectations depending upon a number of factors. These factors
include, among others, those risks and uncertainties that are
described in the definitive proxy statement filed by BIOLASE with
the Securities and Exchange Commission (the “SEC”) in connection
with the Annual Meeting and in the “Risk Factors” section of
BIOLASE’s most recent annual report on Form 10-K filed with the SEC.
Except as required by law, BIOLASE does not undertake any
responsibility to revise or update any forward-looking